Page 180 - 2021_04-Haematologica-web

V. Brixner et al.
hematologic malignancies: an observation-
al study. Transfusion. 2018;58(6):1377-
1387.
28. Magron A, Laugier J, Provost P, Boilard E.
Pathogen reduction technologies: the pros and cons for platelet transfusion. Platelets. 2018;29(1):2-8.
29.Rebulla P, Garban F, van der Meer PF, Heddle NM, McCullough J. A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion. 2020;60(6):1267-1277.
30. Kerkhoffs JL, Eikenboom JC, Schipperus MS, et al. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood. 2006;108(9):3210- 3215.
31. Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion ver- sus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309-13016.
32. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strat- egy for hematologic cancers. N Engl J Med. 2013;368(19):1771-1780.
33. Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the preven- tion of bleeding. Cochrane Database Syst Rev. 2017;7(7):CD009072.
34. Garban F, Guyard A, Labussiere H, et al. Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated
platelets in patients with thrombocytope- nia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol. 2018;4(4):468-475.
35. Heddle NM, Cardoso M, van der Meer PF. Revisiting study design and methodology for pathogen reduced platelet transfusions: a round table discussion. Transfusion. 2020;60(7):1604-1611.
36. Osselaer JC, Doyen C, Defoin L, et al. Universal adoption of pathogen inactiva- tion of platelet components: impact on platelet and red blood cell component use. Transfusion. 2009;49(7):1412-1422.
37. Amato M, Schennach H, Astl M, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang. 2017;112(1):47-55.
38. Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Richtlinie Hämotherapie). In: Bundesärztekammer, ed.2019:1-103.
39. Daurat A, Roger C, Gris J, et al. Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: a study from French hemovigilance data. Transfusion. 2016;56(6):1295-1303.
40. Bolton-Maggs PH. SHOT conference report 2016: serious hazards of transfusion - human factors continue to cause most transfusion-related incidents. Transfus Med. 2016;26(6):401-405.
41. Slichter SJ, Pellham E, Bailey SL, et al. Leukofiltration plus pathogen reduction
prevents alloimmune platelet refractoriness in a dog transfusion model. Blood. 2017; 130(8):1052-1061.
42. Jackman RP, Muench MO, Inglis H, et al. Reduced MHC alloimmunization and par- tial tolerance protection with pathogen reduction of whole blood. Transfusion. 2017;57(2):337-348.
43. Saris A, Kerkhoffs JL, Norris PJ, et al. The role of pathogen-reduced platelet transfu- sions on HLA alloimmunization in hemato- oncological patients. Transfusion. 2019; 59(2):470-481.
44. Tardivel R, Vasse J, Gaucheron S, Lebaudy J-P, Lamy de la Chapelle T, Semana G. A comparative study of the efficiency of plas- ma and additive solution preserved platelet concentrates. Vox Sang. 2012;103 (Suppl 1):S247.
45. van der Meer PF, Bontekoe IJ, Daal BB, de Korte D. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution? Transfusion. 2015;55(8):1900-1908.
46. Drawz SM, Marschner S, Yanez M, et al. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions. Transfusion. 2015;55(7):1745-1751.
47. Corash L, Benjamin RJ. The role of hemovig- ilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultravio- let A pathogen reduction treatment model. Transfusion. 2016;56 (Suppl 1):S29-38.
1096
haematologica | 2021; 106(4)